Ignite Creation Date:
2024-05-05 @ 9:36 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00926341
Status:
COMPLETED
Last Update Posted:
2009-06-24
First Post:
2009-06-22
Brief Title:
The Effects of Peroxisome Proliferators Activated Receptor-Gamma PPAR-γ Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome
Sponsor:
Aligarh Muslim University
Organization:
Aligarh Muslim University
Study Overview
Official Title:
A Study on the Effects of Peroxisome Proliferators Activated Receptor-γ Agonists on Certain Biochemical and Inflammatory Markers in Patients With Metabolic Syndrome
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Metabolic syndrome labeled as the worlds latest epidemic is the force behind the global epidemic of Type 2 Diabetes Mellitus and Cardio Vascular Diseases This emerging epidemic is an important public health problem for South Asians in their homeland and worldwide
Pharmacological therapy is a critical step in the management of patients with metabolic syndrome In general treatment for metabolic syndrome that targets all or most of the components of metabolic syndrome is either deficient or non-existent The study presented here is the pioneering work in the management of metabolic syndrome the emerging global epidemic
Pharmacological therapy is a critical step in the management of patients with metabolic syndrome In general treatment for metabolic syndrome that targets all or most of the components of metabolic syndrome is either deficient or non-existent The study presented here is the pioneering work in the management of metabolic syndrome the emerging global epidemic
Detailed Description:
Our understanding of the metabolic syndrome has been improved by the discovery nuclear peroxisome proliferator-activated receptors PPARs PPAR-γ is a nuclear receptor that influences the expression of multiples gene involved in carbohydrate and lipid metabolism At the crossroads of obesity insulin resistance and cardiovascular disease is the nuclear receptor PPAR-γ At present metabolic syndrome can be described as a PPAR-γ agonist resistance syndrome The modulation of PPAR-gamma activity is an interesting therapeutic approach to address multi-component metabolic syndrome and its consequent cardiovascular events
Recent studies have indicated that in addition to anti diabetic properties PPAR-γ agonists TZD-Pioglitazone provides protection against atherosclerotic cardiovascular disease Further the identification of ARBs-Telmisartan and Irbesartan as capable of activating PPAR - γ has provided a novel approach in treating hypertension insulin resistance hyperlipidemia and inflammation
Emerging evidence suggests that PPAR-γ agonist Thiazolidinediones TZD-Pioglitazone is an insulin sensitizer and modulator of metabolic syndrome through its pleiotropic effects on vascular risk and have beneficial effects on systemic inflammatory markers Despite the beneficial effects of full PPAR- agonists like the TZDs recent evidence suggests that full PPAR- agonists are less than optimal agents in patients with metabolic syndrome TZDs promote adipo-genesis and fluid retention causing weight gain and precipitate congestive heart failure The adverse effects of full PPAR- agonists like the TZDs have reinforced the need to identify additional therapies with insulin-sensitizing properties The recent discovery that telmisartan an angiotensin II type 1 receptor AT1-R blockers ARBs is uniquely capable of selective PPAR- -modulating activities have the potential to treat both hemodynamic and biochemical features of insulin resistance and metabolic Syndrome
Recent studies have indicated that in addition to anti diabetic properties PPAR-γ agonists TZD-Pioglitazone provides protection against atherosclerotic cardiovascular disease Further the identification of ARBs-Telmisartan and Irbesartan as capable of activating PPAR - γ has provided a novel approach in treating hypertension insulin resistance hyperlipidemia and inflammation
Emerging evidence suggests that PPAR-γ agonist Thiazolidinediones TZD-Pioglitazone is an insulin sensitizer and modulator of metabolic syndrome through its pleiotropic effects on vascular risk and have beneficial effects on systemic inflammatory markers Despite the beneficial effects of full PPAR- agonists like the TZDs recent evidence suggests that full PPAR- agonists are less than optimal agents in patients with metabolic syndrome TZDs promote adipo-genesis and fluid retention causing weight gain and precipitate congestive heart failure The adverse effects of full PPAR- agonists like the TZDs have reinforced the need to identify additional therapies with insulin-sensitizing properties The recent discovery that telmisartan an angiotensin II type 1 receptor AT1-R blockers ARBs is uniquely capable of selective PPAR- -modulating activities have the potential to treat both hemodynamic and biochemical features of insulin resistance and metabolic Syndrome
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None